Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer.

Next Previous
Trial Profile

A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pictrelisib (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Genentech; Roche

Most Recent Events

  • 06 Oct 2017 Results assessing safety, tolerability, and pharmacokinetics of pictilisib administered with paclitaxel and carboplatin with or without bevacizumab in patients with NSCLC or pemetrexed and cisplatin with and without bevacizumab in patients with non-squamous NSCLC, were published in the European Journal of Cancer.
  • 26 Jan 2016 According to ClinicalTrials.gov record,primary end points has been revised and no.of treatment arms changed from 3 to 4.
  • 22 Mar 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top